LENSAR INC

LNSRNASDAQ

🏆 #3225 by market capEarnings Aug 13 · PreUS Equity

$129.48▲ $8.68 (+6.70%)

Simulated price

1h—

24h▲ 6.7%

7d—

14d—

30d—

1y—

🏦Market Cap

$73M

Small Cap

📈Revenue Growth (YoY)

+1.1%

Slowing

📊Gross Margin

45.7%

Healthy

💵FCF Margin

—

⚖️P/S Ratio

1.3x

Cheap

Otter Score

Fair

No chart data available for LNSR.

Trading Snapshot

Day Range: $127.99 – $131.82
52-Week Range: $4.95 – $13.08
Volume: $4.78B
Avg Volume: $6.23B
Shares Outstanding: 12.3M
Next Earnings: Oct 5, 2026

Fundamentals Snapshot

Annual Revenue: $58M
Last Q Revenue: $13M
P/E Ratio: 2.5
P/S Ratio: 1.3x
EPS (TTM): $1.78
Dividend Yield: —

Why Investors Own LNSR

✓High-growth profile — revenue up +52.9% YoY with expanding US Equity exposure.
✓Healthy economics — 77% gross margin and 16% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$58M▲ +49.2% YoY

Gross Margin (TTM)

76.5%▼ −0.1% YoY

Operating Income (TTM)

$10M▲ +49.2% YoY

Free Cash Flow (TTM)

$9M▲ +49.2% YoY

About LENSAR INC

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

🦦